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Context: Mutations in Cytochrome P450 oxidoreductase (POR) cause a form of congenital adrenal 
hyperplasia (CAH). We are reporting a novel R550W mutation in POR identified in a 46, XX patient 
with signs of aromatase deficiency.  
 
Objective: Analysis of aromatase deficiency from R550W mutation in POR. 
 
Design, setting, and patient: Both the child and the mother had signs of virilization. Ultrasound 
revealed the presence of uterus and ovaries. No defects in CYP19A1 were found, but further analysis 
with a targeted Disorders of Sexual Development NGS panel (DSDSeq.V1, 111 genes) on a NextSeq 
(Illumina) platform in Madrid and Barcelona, Spain, revealed compound heterozygous mutations 
c.73_74delCT/p.L25FfsTer93 and c.1648C>T/p.R550W in POR. WT and R550W POR were produced 
as recombinant proteins and tested with multiple cytochrome P450 enzymes at University Children’s 
Hospital, Bern, Switzerland. 
 
Main outcome measure and Results: R550W POR showed 41% of the WT activity in cytochrome c 
and 7.7% activity for reduction of MTT. Assays of CYP19A1 showed a severe loss of activity and 
CYP17A1, as well as CYP21A2 activities, were also lost by more than 95%. Loss of CYP2C9, 
CYP2C19, and CYP3A4 activities was observed for the R550W-POR. Predicted adverse effect on 
aromatase activity as well as a reduction in binding of NADPH was confirmed.  
 
Conclusions: Pathological effects due to POR R550W were identified, expanding the knowledge of 
molecular pathways associated with aromatase deficiency. Screening of the POR gene may provide a 





In a 46, XX patient with aromatase deficiency, a mutation in POR was identified, which inhibited 
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Cytochrome P450 oxidoreductase (POR) is the redox partner of cytochrome P450 proteins located in 
the endoplasmic reticulum (1). POR deficiency (PORD, OMIM: MIM613571 and MIM201750) is a 
form of congenital adrenal hyperplasia, initially described in patients with altered steroidogenesis (2-4) 
followed by several reports with a broad spectrum of disorders (5-7). In 2004, mutations in POR 
disrupting steroid biosynthesis were reported (2,6,7), and in subsequent reports, a range of POR 
mutations causing disorders of sexual development with and without bone malformation have been 
described (5,8-11). Human POR is a 680 amino acid protein that has evolved from ferredoxin and 
ferredoxin reductase-like domains to form a single redox protein in eukaryotes. POR was identified by 
studies of Lu and Coon as a component of microsomal mixed oxidase system along with lipids and 
cytochrome P450 proteins (12). POR transfers redox equivalents from the reduced form of nicotinamide 
adenine dinucleotide phosphate (NADPH) to cytochrome P450 proteins for their catalytic activities (13) 
(Figure 1). Also, POR can reduce heme oxygenase, cytochrome b5, and a range of small molecules and 
dyes like ferricyanide (FeCN), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), 
etc (1,14). Due to its unique role in a range of metabolic processes, POR is an essential protein and 
POR knockout mouse are embryonically lethal (15). POR deficiency was initially identified as a 
disorder of sex development with ambiguous genitalia resembling some features of Antley-Bixler bone 
malformation syndrome. However, after findings of multiple genetic defects in POR from patients both 
with and without bone malformation features, PORD is now considered a separate genetic disorder 
different from the Antley-Bixler syndrome which is due to presence of mutations in fibroblast growth 
factor receptor 2 (FGFR2) and without defects in steroid metabolism (1,8,16-18).  
 
Due to the involvement of POR in multiple reactions in the metabolism of both the steroids and drugs, 
exact effects of individual mutations in POR are hard to predict and require extensive characterization 
by enzymatic and biochemical analysis (2,8,19-26). Therefore, the exact mechanisms by which 
mutations in POR cause pathogenesis, remain mostly unknown. From the characterization of multiple 
mutations in POR by us as well as other laboratories, some general conclusions could be drawn. 
Mutations in POR that result in loss of flavin co-factors (FAD and FMN) show a severe loss of 
enzymatic activities and cause a lethal form of POR deficiency. Mutations located in the hinge region 
of POR that is necessary for FMN and FAD domain movements cause a phenotypically variable form 
of the disease and impact different P450 enzyme activities to different extents. Mutations located near 
the NADPH binding site of POR may impact the activities of multiple cytochrome P450 activities, but 
the impact on individual enzymes could be variable. We have reported a study of structural stability 
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Aromatase is a 503 amino acid protein (NP_000094) encoded by the CYP19A1 gene (MIM10790, 
GeneID:1588, NCBI: NM_000103), located on chromosome 15 (15q21.2, GRCh38 15:51208056-
51338597). CYP19A1 (EC: 1.14.14.14) regulates estrogen biosynthesis in humans (28) by converting 
androgens to estrogens (29-32). Aromatase is highly expressed in ovaries and plays a significant role 
in the regulation of the reproductive cycle in females (33). Some of the critical reactions catalyzed by 
aromatase include the conversion of androstenedione to estrone (E1), testosterone to 17β-estradiol (E2) 
and 16-hydroxytestosterone to estriol (E3) (28). The catalytic process of aromatization of androgens is 
multifaceted, and it comprises of three steps involving the transfer of three pairs of electrons from the 
reduced form of nicotinamide adenine dinucleotide phosphate (NADPH) and consumption of oxygen. 
Electron transfer from NADPH to aromatase is carried out by NADPH cytochrome P450 
oxidoreductase (POR).  
 
The first case of placental aromatase deficiency was reported by Shozu et al. (34), and aromatase 
deficiency manifests during fetal life in both sexes (35). Multiple genetic defects are associated with 
decreased aromatase expression in both male and female reproduction (36). In females, aromatase 
deficiency affects maternal virilization during gestation, abnormal external genitalia in the female fetus, 
normal ovarian development but increased polycystic ovary syndrome occurrence and virilization at 
puberty (37,38). Impact of aromatase deficiency on growth, skeletal maturation, and bone homeostasis, 
as well as changes in insulin resistance and abnormal plasma lipid profile, have been described in earlier 
studies (39,40). In a Japanese cohort of PORD patients, homozygous mutation R457H has been linked 
to genital virilization and aromatase deficiency in 46, XY patients (11) and some earlier cases of 
aromatase deficiency have been confirmed as PORD in later analysis (41). 
 
Here we have performed a detailed characterization of a novel mutation in POR, R550W, that caused 
aromatase deficiency in a 46, XX patient and led to maternal virilization during pregnancy. By use of 
biochemical analysis of patient samples and production of a recombinant form of POR containing the 
R550W mutation, we have been able to characterize the different enzyme activities affected by the 
R550W mutation in POR. We investigated the effect of R550W mutation in POR on steroid 
metabolizing P450 enzymes CYP17A1 (17-hydroxylase activity), CYP21A2 (21-hydroxylase activity) 
and CYP19A1 (aromatase activity) and could show that CYP19A1 activity was severely affected by 
the R550W mutation in POR, explaining the cause of virilization observed the in 46, XX female child. 
Since POR is the redox partner of hepatic drug metabolizing cytochrome P450 enzymes, a mutation in 
POR may also affect drug metabolism (Figure 2). A large number of drugs are metabolized by 
cytochrome P450 enzymes in the liver. The major hepatic drug metabolizing enzyme is CYP3A4, which 
alone metabolizes almost half the drugs in clinical use (42-44). Therefore, we also tested the effect of 
R550W mutation in POR on activities of four drug-metabolizing cytochromes P450 (CYP2C9, 
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molecules (FeCN and MTT) and a soluble probe substrate cytochrome c, to identify different 
mechanisms that may affect POR due to R550 mutation. Our experiments identified two distinct 
mechanisms for pathogenicity of the POR mutation R550W: inhibition of CYP19A1 activity leading to 
virilization of the female child, and the overall reduction in the activities of POR due to loss of flavin 
content, suggesting protein instability. These results expand our knowledge about the pathology of 
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Case Report and Methods 
 
Patient 
The patient was born at term in Málaga (Spain) in 2009, from the 1st pregnancy of non-consanguineous 
parents. The mother had presented signs of virilization from the 6th month of pregnancy (acne, hirsutism, 
clitoris growth, and voice deepening) that regressed progressively post-partum. Hormone analyses at 
post-partum day 5 revealed a highly increased testosterone (T) serum concentration that returned to 
normal female levels at the fourth postpartum month (Table 1). The child was examined at seven days: 
length 48 cm (-1.22 SDS), weight 2,920 g (-1.02 SDS), the external genitalia showed a rugated labia 
majora, no palpable gonads, genital tubercle of 1.5 cm with proximal urethral opening, considered as 
Prader type 3 ambiguous genitalia. At three months, clitoris hypertrophy had regressed. Initial (7 days 
of age) 17-OH-P and T were elevated and progressively diminished; T reached normal female levels 
from the 1st month, whereas 17-OH-P was still slightly elevated at seven months (Table 1). The 
karyotype was 46, XX, and 21-hydroxylase deficiency was ruled out since the 17-OHP increased at 
birth, but the values were below those seen in the classic form of 21-hydroxylase deficiency and showed 
a progressive reduction. Pelvic ultrasound revealed the presence of uterus and bilateral gonads. 
Transient intrauterine virilization was diagnosed due to maternal pregnancy luteoma or aromatase 
deficiency that would explain the transient virilization of the mother and the female child. The CYP19A1 
gene was sequenced from the DNA of the child, but no pathogenic sequence variant was detected. The 
patient developed without any further significant clinical manifestations. A genitoplasty was performed 
at 13 months. At 8 years, there were no signs of adrenarche (no pubic hair) and bone age was 7 years, 
indicating that there was no increase in androgen levels, despite the elevated 17-OH-P levels. 
 
Hormone assays 
Hormone assays were performed in Málaga (Hospital Carlos Haya), Spain. The 17-OH-P was 
determined with a commercial radioimmunoassay technique (Coat-A-Count. Siemens Healthcare 
Diagnostics Ltd. Frimley, Camberley, UK); dehydroepiandrosterone sulfate (DHEA-S), T, estradiol 
(E2) and cortisol were determined with automated electrochemiluminescent assays (Modular E, Roche 
Diagnostics GmbH Mannheim, Germany) and ACTH with an automated chemiluminescence 
immunoassay (LIAISON, DiaSorin, Saluggia, Italy).  
 
Genetic studies 
The study was approved by the Ethics Committee of Hospital Universitari Vall d'Hebron (CEIC), 
Barcelona, Spain (PR (IR) 23/2016) and parents provided informed consent. Genomic DNA was 
isolated from whole peripheral blood samples from the patient and her family using standard 
procedures. The DNA samples were analyzed with a custom-designed targeted Disorders of Sexual 
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technology (Roche Nimblegen) and sequenced on a NextSeq500 platform (Illumina) platform. All 
procedures were carried out according to the manufacturer´s instructions. Data analyses were performed 
using VariantStudio V2.2.1 (Illumina) and in-house bioinformatic analysis as previously described (45).  
The observed variants were evaluated using the Alamut Visual software v2.11 (https://www.interactive-
biosoftware.com/es/alamut-visual/, which includes following pathogenicity prediction tools: Mutation 
Taster, PolyPhen, Align GVGD and SIFT) MutAssesor, Fasthmm, Vest and CADD V1.4 
(https://cadd.gs.washington.edu/). Genome Aggregation Database (gnomAD, 
http://gnomad.broadinstitute.org), dbSNP (https://www.ncbi.nlm.nih.gov/snp/) and the Collaborative 
Spanish Variant Server (CSVS; CIBERER BIER, Valencia, Spain; http://csvs.babelomics.org/) were 
consulted for allelic frequencies. Candidate variants observed by targeted panel (DSDSeq.V1) 
sequencing as well as segregation analysis in the family were validated and genotyped by Sanger 
sequencing. Variant classification was performed according to ACMG recommendations (46). 
 
Materials 
Tris-base, NADPH, acetic acid, magnesium acetate, Sucrose, potassium phosphate EDTA, DTT, 
glycerol, PMSF, and Benzonase were purchased from Sigma-Aldrich Chemie GmbH (Buchs, 
Switzerland). Carbenicillin, FeCl3, ZnCl2, CoCl2, Na2MoO4, CaCl2, CuCl2, M H3BO3 were purchased 
from CarlRoth GmBH (Switzerland).  Goat anti-rabbit antibodies labeled with infra-red dyes were from 
LI-COR Bioscience Inc. (NE, USA). The RC-DC protein assay dye reagent was from Bio-Rad 
(Hercules, CA). The anti-POR antibody was from GenScript (NJ, USA). BOMCC (Invitrogen Corp, 
Carlsbad, CA, United States). 
 
Expression of POR proteins in bacteria and membrane purification 
The human POR WT and R550W mutant proteins (NCBI# NP_000932, UniProt#  P16435) were 
expressed in bacteria using heterologous gene expression (8,20,26,47). The protocol for recombinant 
expression of POR variants (N-23 form) and subsequent bacterial membrane purification was based on 
our previous publications (8,23,24,26,48) with slight modification. Briefly, plasmid (pET15b) 
containing cDNAs for WT or mutant POR were obtained from GenScript. The Escherichia coli 
bacterial strain BL21(DE3) was transformed, and single colonies were selected for growth on 
carbenicillin plate. For the main shake flask culture, autoinduction media consisting of terrific broth 
supplemented with 40 mM FeCl3, 4 mM ZnCl2, 2 mM CoCl2, 2 mM Na2MoO4, 2 mM CaCl2, 2 mM 
CuCl2, 2 mM H3BO3, 0.5 mg/ml riboflavin, 100 µg/ml carbenicillin was used. The cells were grown at 
37 °C to an optical density (OD) at 600 nm of 0.6, and then the temperature was reduced to 25 °C and 
further grown for 16 h. The bacterial cells were collected by centrifugation, washed with PBS and 
slowly stirred for 1 h at 4°C for in 50 mM Tris-acetate (pH 7.6), 0.25 M sucrose, 0.5 mM EDTA, 
lysozyme (0.2 mg/ml), 1 mM PMSF and 20 U/ml endonuclease to prepare spheroplasts. The 
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potassium phosphate (pH 7.6) containing 6 mM Magnesium acetate, 0.1 mM DTT, 20% (v/v) glycerol 
and 1 mM PMSF; and disrupted by sonication. After centrifugation at 12000 × g for 15 min at 4 °C, the 
supernatant was centrifuged at 100000 × g for 90 min at 4 °C to collect membranes. Purified membranes 
containing POR were resuspended in 50 mM Potassium phosphate buffer (pH 7.8) and 20% (v/v) 
glycerol and kept at −70 °C. Protein concentration was measured by the RC-DC protein assay method 
(Protein Assay Dye Reagent, Bio-Rad, Hercules, CA) and POR content in membrane proteins was 
measured by western blot analysis.  
 
Western Blot Analysis of POR Content in the Bacterial Membranes  
Western blot analysis to determine POR content in membranes was done as described previously 
(24,49). Briefly, 1 μg of bacterial membrane proteins were separated on an SDS-PAGE gel and blotted 
on to polyvinyl difluoride (PVDF) membranes. Blots were first incubated with a rabbit polyclonal 
antibody against POR-WT from GenScript (GenScript, NJ, USA) at a dilution of 1:1000. We then used 
a secondary goat anti-rabbit antibody labeled with an infrared dye (IRDye 680RD, LI-COR Bioscience 
Inc., NE, USA) at a 1:15000 dilution. Signals were analyzed with the 700 nm fluorescent channel on 
an Odyssey Infrared Imaging System (LI-COR Bioscience Inc., NE, USA), and protein bands were 
quantitated using the Odyssey software (LI-COR Bioscience Inc., NE, USA). Purified wild-type POR 
was used as a standard for normalizing the POR content of each membrane preparation in all 
experiments described here, the normalized amount of POR content was used for POR-WT and POR-
P550W protein. 
 
Small molecule Reduction Assay by POR-WT and POR-R550W 
Cytochrome c reduction by POR-WT or POR-R550W was performed as described previously by 
measuring the change in absorbance at 550  nm (ε=21.1  cm−1 mM−1) (50). In brief, varying 
concentrations of cytochrome c (1.3–40 μM) were mixed with membrane preparations containing 1 µg 
POR in 100 mM phosphate buffer (pH 7.6) in a total volume of 100 l. The reaction was started by the 
addition of NADPH, and the change in absorbance at 550 nm was monitored over 6 minutes. The 
reaction was performed in 96-well plates, in triplicate, using a microplate reader (Spectramax M2e, 
Molecular Devices, Sunnyvale, CA). Data were fitted based on Michaelis-Menten kinetics using 
GraphPad Prism (GraphPad Software, La Jolla, CA USA) to determine the Vmax and Km. The MTT [3-
(4,5-dimethylthiazol- 2-yl)-2,5-diphenyltetrazolium] reduction assay was carried out using different 
concentrations of MTT (3.9-500 μM), by measuring the rate of increase in absorbance at 610 nm ( 
ε610=11 mM-1 cm-1) (51). The reaction mixture consisted of bacterial membranes containing 1 µg POR 
in 100 mM phosphate buffer (pH 7.6) and 100 M NADPH. Similarly, the ferricyanide reduction was 
measured as the rate of decrease in absorbance at 420 nm (ε420=1.02 mM-1 cm-1). The reaction was 









niversitaetsbibliothek Bern,  am
it@













(52). Activities represent the mean of at least three replicates. For NADPH variation analysis, 
cytochrome c (40 M) and MTT (500 M) were kept constant, and NADPH concentration was varied 
from 0.8-100 M. 
 
Flavin Content Analysis of WT and Mutant POR 
Flavins were extracted by thermal denaturation of POR proteins and analyzed as described previously 
(53). POR-WT or POR-R550W (100 µg/ml) were denatured by heating at 95 °C for 10 min in the dark 
and flavins were separated by centrifugation at 14000 x g for 10 min from the precipitated protein. The 
fluorescence of the supernatants was measured at pH 7.7 and pH 2.6 to determine FMN and FAD ratio 
(excitation at 450 nm, emission at 535 nm). 
 
Expression and Purification of human CYP19A1 
The recombinant human CYP19A1 was expressed and purified, as described previously (54) with some 
modifications. Briefly, a single colony of E. coli BL21(DE3) transformed with expression vectors for 
CYP19A1, and molecular chaperones GroEL/GroES, was selected for protein expression. A 1:100 
dilution of overnight growth culture was used to inoculate the autoinduction medium (terrific broth, 40 
mM FeCl3, 4 mM ZnCl2, 2 mM CoCl2, 2 mM Na2MoO4, 2 mM CaCl2, 2 mM CuCl2, 2 mM H3BO3, 100 
µg/ml carbenicillin and 50 µg/ml kanamycin).  After 4 h of incubation at 25°C, 1 mM δ-aminolevulinic 
acid and 4 mg/ml arabinose (for induction of molecular chaperones GroEL/GroES) were added, and the 
culture was grown for another 20 h. Bacteria were then harvested, washed with PBS, and stored at -80 
°C. Bacterial pellet was resuspended in 50 mM Tris-Acetate (pH 7.6), 250 mM sucrose, 0.5 mM EDTA, 
and 0.2 mg/ml lysozyme to prepare spheroplasts. For purification, spheroplasts were lysed using 10 x 
CellLytic B (Sigma-Aldrich) in a 100 mM potassium phosphate (pH 7.4) buffer containing 20% 
glycerol, 500 mM sodium acetate, 0.1 mM DTT, 0.1 mM EDTA and 1 mM PMSF. The supernatants 
after centrifugation were pooled and CYP19A1 was purified by Ni2+ metal-chelate chromatography at 
4 °C using 200 mM histidine for elution. Eluted protein was dialyzed to remove histidine, and protein 
concentration was determined by RC-DC protein assay (Protein Assay Dye Reagent, Bio-Rad, 
Hercules, CA) using BSA as standard. 
 
Cytochrome P450 CYP17A1 enzyme activity supported by WT and POR-R550W 
Purified recombinant CYP17A1 was used to test the effect of POR-R550W to support the 17α-
hydroxylase activity of CYP17A1. Bacterial membranes containing POR and purified CYP17A1 
(CYPEX, Dundee, Scotland, United Kingdom) were reconstituted as described previously (8,49,55,56) 
and 17α-hydroxylase activity of CYP17A1 was measured by using progesterone as substrate. The 
reaction mixture consisted of 30 pmol of CYP17A1, 60 pmol of POR, and 14C labeled progesterone 
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with 10 mM magnesium chloride, 6 mM potassium acetate, and 1 mM reduced glutathione. 
Progesterone concentration was varied from 0.3 µM to 5 µM for kinetic analysis, and the reaction was 
initiated by the addition of 2 mM NADPH and incubated for 60 min at 37 °C. Data were fitted based 
on Michaelis-Menten kinetics using GraphPad Prism (GraphPad Software, La Jolla, CA USA). 
 
Assay of cytochrome P450 CYP21A2 enzyme activity supported by WT and POR-R550W 
Purified recombinant CYP21A2 was used to test the effect of POR-R550W to support the 21-
hydroxylase activity of CYP21A2. Bacterial membranes containing POR and purified CYP21A2 
(CYPEX, Dundee, Scotland, United Kingdom) were reconstituted as described previously (8,49,55,56) 
and 21-hydroxylase activity of CYP21A2 was measured using progesterone as the substrate. The 
reaction mixture consisted of 20 pmol of CYP21A2, 40 pmol of POR, and 14C labeled progesterone 
(50000 cpm) in 50 mM potassium phosphate buffer (pH 7.4). The reaction mixture was supplemented 
with 10 mM magnesium chloride, 6 mM potassium acetate, and 1mM reduced glutathione. Different 
concentrations (0.3–5 µM) of progesterone were used for kinetic analysis, and the reaction was initiated 
by the addition of 2 mM NADPH and incubated for 60 min at 37 °C. Data were fitted based on 
Michaelis-Menten kinetics using GraphPad Prism (GraphPad Software, La Jolla, CA USA). 
 
Cytochrome P450 CYP19A1 enzyme activity supported by WT and POR-R550W 
Purified recombinant CYP19A1 using the bacterial expression system was used to test the effect of 
POR-R550W to support the aromatase activity. Aromatase activity was measured by the tritiated water 
release assay based on an earlier method described by Lephart and Simpson (57) with some 
modifications (26,49) using a reconstituted system and androstenedione (androst-4-ene-3,17-dione) as 
the substrate. Bacterial membranes containing POR and purified CYP19A1 were reconstituted in a 1:2 
ratio.  Reaction mixture consisted of 50 pmol of POR, 100 pmol of CYP19A1 and tritium labeled 
androstenedione ([1ᵝ-3H(N)]-andros-tene-3,17-dione; ~15,000 cpm) in 100 mM potassium phosphate 
buffer (pH 7.4) with 100 mM NaCl. Different concentrations (10–1000 nM) of androstenedione were 
used for kinetic analysis. The aromatase reaction was started by addition of 1 mM NADPH and was 
incubated for 60 min at 37 °C. After incubation, 0.8 ml of 5% charcoal/0.5% dextran solution was added 
to the reaction mixture. Reaction tubes were mixed by vortex and centrifuged at 15000 x g for 5 minutes. 
From each tube, 0.5 ml of supernatant was used for radioactivity measurement. Values obtained from 
duplicate experiments are expressed as mean ± S.E.M. (standard error of the mean). Data were fitted 
based on Michaelis-Menten kinetics using GraphPad Prism (GraphPad Software, La Jolla, CA USA). 
For NADPH kinetic analysis, androstenedione concentration was kept constant at 100 nM, and NADPH 
was varied from 62.5-1000 µM. 
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The activity of CYP2C9 supported by WT or mutant POR was tested using in vitro reconstituted system. 
It consisted of bacterial membranes containing WT/R550W POR, purified CYP2C9 (CYPEX, Dundee, 
Scotland, United Kingdom) and purified cytochrome b5 at a ratio of 5:1:1 (58). The fluorogenic 
compound BOMCC (7-Benzyloxy-4-trifluoromethylcoumarin) (Invitrogen Corp, Carlsbad, CA, United 
States) was used as substrate. 100 µL of assay mixture consisted of 5 µg DLPC (1,2-Dilauroyl-sn-
glycero-3-phosphocholine), 3 mM MgCl2 and 20 µM BOMCC in 100 mM Tris-HCl buffer (pH 7.4). 1 
mM NADPH was added to start the reaction and fluorescence was measured on a Spectramax M2e 
plate reader (Molecular Devices, Sunnyvale, CA, United States) at an excitation wavelength of 415 nm 
and an emission wavelength of 460 nm for BOMCC. 
 
Cytochrome P450 CYP2C19 activity supported by WT and POR-R550W 
The activity of CYP2C19 supported by WT or POR-R550W was tested using the fluorogenic substrate 
EOMCC (Invitrogen Corp, Carlsbad, CA, United States). In vitro, CYP2C19 assays were performed 
using a reconstituted system consisting of WT/POR-R550W, CYP2C19 (CYPEX, Dundee, Scotland, 
United Kingdom) and cytochrome b5 at a ratio of 5:1:1 (58). It consisted of 2.5 µg DLPC and proteins 
(0.5 µM POR: 100 nM CYP2C19: 100 nM b5), 3 mM MgCl2, 20 µM EOMCC in 100 µL of 100 mM 
Tris-HCl buffer (pH 7.4). The reaction was started by addition of 0.5 mM NADPH, and fluorescence 
was measured on a Spectramax M2e plate reader (Molecular Devices, Sunnyvale, CA, United States) 
at an excitation wavelength of 415 nm and an emission wavelength of 460 nm for EOMCC. 
 
Cytochrome P450 CYP3A4 Activity supported by WT and POR-R550W 
The activity of the major drug-metabolizing enzyme CYP3A4 supported by WT or POR-R550W was 
tested using the fluorogenic substrate, BOMCC, as described earlier (59). An in-vitro reconstituted 
system was used by mixing POR (WT or R550W), purified CYP3A4 (CYPEX, Dundee, Scotland, UK) 
and cytochrome b5 as described above at a ratio of 5:1:1 (58). The final assay mixture consisted of 
proteins (1 µM POR: 200 nM CYP3A4: 200 nM b5), 3 mM MgCl2, 5 µg DLPC and 20 M BOMCC 
in 100 µL of 100 mM Tris-HCl buffer (pH 7.4).  1 mM NADPH was added to start the reaction and 
progress of the reaction was monitored by fluorescence Spectrophotometer (Spectramax M2e plate 
reader; Molecular Devices, Sunnyvale, CA) with sample excitation at 415 nm and emission at 460 nm. 
 
Cytochrome P450 CYP3A5 activity supported by WT and POR-R550W 
The activity of CYP3A5 supported by WT or POR-R550W was tested using the in-vitro reconstituted 
system as described above. The purified CYP3A5 (CYPEX, Dundee, Scotland, United Kingdom), 
WT/mutant POR, and cytochrome b5 were mixed at a ratio of 1:5:1 (58). The assay mixture (100 µL) 
consisted of 5 µg DLPC and proteins (1 µM POR: 200 nM CYP3A5: 200 nM b5), 3 mM MgCl2, 20 µM 
BOMCC in 100 mM Tris-HCl buffer (pH 7.4) and the reaction was started by addition of NADPH to 1 









niversitaetsbibliothek Bern,  am
it@














3D protein models 
To study the potential impact of the mutation on structure, 3D models of POR-WT and POR-R550W 
were prepared using previously published model building protocols.  
 
Statistical Analysis of results 
Data are shown as mean, standard errors of the mean (SEM) in each group or replicates. Differences 
within the subsets of experiments were calculated using Student’s t-test. P values less than 0.05 were 





Identification of compound heterozygous variants in POR in CYP19A1 deficiency 
Custom-designed targeted DSD NGS panel (DSDSeq.V1) revealed compound heterozygous variants 
in POR (NM_000941.2): c.73_74delCT/p.(L25Ffs*93) and c.1648C>T/p.(R550W) in the patient (46, 
XX karyotype). Sanger sequencing confirmed the segregation, the mother carried for the frameshift 
c.73_74delCT/p.(L25Ffs*93) and the father for the missense variant, c.1648C>T/p.(R550W) (Figure 
3). A younger normal brother carried the c.1648C>T p.( R550W) variant. No further variants of interest 
were identified in the DSDSeq.V1 panel. At 8 years, the patient is prepubertal, and growth is normal 
(height 0.1 SDS and weight -0.41 SDS). No skeletal anomalies were detected, and the baseline 
hormonal analysis revealed normal DHEA-S, cortisol, T, and ACTH while 17OH-P was elevated (Table 
1). Recommendations related to the stress situation needing glucocorticoid therapy were given to 
parents.  
 
Both POR variants found in the patient are observed as rare variants in genome databases  
The POR variants identified in the patient in this report have been observed as rare variants in the 
genome databases (Table 2). The Arginine 550 residue studied here is highly conserved across species. 
The variant c.1648C>T/p.(R550W) (rs782551496) which has a MAF of 0.00004671 (GnomAD) was 
classified as a variant of uncertain significance (VUS) and predicted to be pathogenic with multiple 
pathogenicity prediction tools. Another variant at the same position, R550Q only had data available for 
the Global population (Table 2). The variant c.73_74delCT/p.(L25Ffs*93) (rs782696006) has a 
population minor allele frequency (MAF) of 0.000008125 (GnomAD), is classified as likely pathogenic 
following recommendations of ACGM, and due to truncation would generate a non-functional POR 










niversitaetsbibliothek Bern,  am
it@













Arginine 550 is located near NADPH binding site in POR and mutation R550W creates protein 
instability 
To differentiate between the POR-WT and POR-R550W, we performed in-silico mutagenesis using the 
x-ray crystal structure of human POR. Human POR has distinct domains for the binding of 
NADPH/FAD and FMN (Figure 4A). The FMN binding domain interacts with the redox partners and 
is required for electron transfer to partner proteins. The redox equivalents for the electron transfer are 
provided by NADPH which is used as a substrate by POR and converted to NADP. The R550 residue 
is not directly at the surface of POR but is located near the NADPH binding pocket (Figure 4B).  In 
the WT-POR, the arginine 550 residue forms hydrogen bonds with threonine 529 to stabilize the 
NADPH binding domain (Figure 4C). Mutation of arginine 550 to tryptophan results in loss of 
hydrogen bond interactions and destabilization of the POR protein. Binding of NADPH has also been 
associated in providing stability to POR and disruption of NADPH binding due to mutation of arginine 
550 to tryptophan is predicted to cause protein instability. 
 
The R550W mutation in POR results in reduced flavin content  
To differentiate the conformational changes and effects of POR mutation R550W on flavin binding, we 
evaluated the relative flavin content since the activity of POR may be affected by the changes in the 
binding of cofactors FMN and FAD. As compared to WT POR, both the FMN and the FAD-binding 
was affected due to R550W mutation. As compared to WT, the FMN and FAD content of POR-R550W 
was 63.4% and 68.7 % respectively. This suggests that POR-R550W affects both FMN as well as FAD 
binding to POR (Figure 5). Since the R550 residue is not directly involved in either the FAD or the 
FMN binding, loss of flavins suggests an overall instability of protein due to R550W mutation. It has 
been shown previously that binding of NADPH may affect the FAD/FMN binding in POR, and 
therefore, R550W mutation in POR may create a conformational change that is less favorable for the 
binding of FAD as well as FMN. 
 
Small molecule Reduction Activity of POR is adversely affected by the R550W mutation. 
To study the effect of the R550W mutation on POR activity, we expressed WT and POR- R550W in E. 
coli as N-23 form and purified bacterial membranes. The ability to transfer electrons from NADPH to 
cytochrome c, MTT or ferricyanide by POR-WT or POR-R550W was tested.  The POR-R550W 
mutation had a much lower capacity to reduce cytochrome c, MTT, and ferricyanide (Table 3, Figure 
6A-C). Compared to WT POR, the R550W variant lost ~60% cytochrome c reduction activity and 
~70% of ferricyanide reduction activity. The MTT reduction activity (Table 3, Figure 6B) was also 
severely affected by the R550W mutation, with only 8% residual activity observed compared to WT-
POR. The loss of activities with ferricyanide indicates disruption of electron transport from NADPH to 
FAD and loss of cytochrome c and MTT reduction activities indicates disruption of electron transfer 
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R550W mutation might be affecting domain movements and transfer of electrons from NADPH to 
FAD, FMN, and acceptor molecules. Since Ferricyanide reduction can proceed even without a 
functional FMN domain in POR, loss of Ferricyanide reduction activity could either be due to a 
disruption of electron transfer from NADPH to FAD or the loss of FAD-binding as reported above and 
a combination of these two factors. The cytochrome c and MTT reduction by POR requires a functional 
FMN domain in addition to the intact NADPH/FAD-binding domain. However, we have seen MTT 
reduction activity to be a better indicator of the effect on steroid metabolizing enzymes, and here the 
loss of MTT reduction activity was much severe compared to a loss of cytochrome c reduction activity. 
 
CYP17A1- 17α-hydroxylase Activity 
After the observation of lower activities of the R550W mutant of POR towards the reduction of small 
molecule substrates, we sought to examine the effect of arginine to tryptophan at the position 550 in 
POR on the activities of several steroid metabolizing cytochrome P450 enzymes that are dependent on 
POR for their enzymatic reactions. Towards this goal, we first examined the effect of POR-R550W on 
the 17-hydroxylase activity of CYP17A1, which is considered the qualitative regulator of 
steroidogenesis in human and guides the formation of steroids towards different pathways. The POR- 
R550W lost almost all 17α-hydroxylase activity of CYP17A1 (Figure 7A, Table 3). For the POR-
R550W variant, the apparent Vmax was reduced by ~95% without affecting the apparent Km as 
compared to WT POR. The POR variant R550W showed only 3% residual activity in supporting 
CYP17A1 as compared to WT POR.  
 
The 21-hydroxylase activity of CYP21A2 is severely affected by the R550W mutation in POR 
The CYP21A2 is involved in the regulation of corticosteroids and is a critical enzyme in the steroid 
metabolism in human. Defects in CYP21A2 cause the most common form of congenital adrenal 
hyperplasia and mutation in POR may resemble CYP21A2 deficiency due to adverse effects of a 
malfunctioning POR on the activities of CYP21A2. The POR-R550W showed highly reduced 
CYP21A2 activity (Figure 7B, Table 3). The apparent Vmax of POR-R550W was reduced by ~98%. 
The POR variant R550W showed only 3 % residual activity in supporting CYP21A2 as compared to 
WT POR.  
 
POR mutation R550W causes severe disruption of the aromatase activity of CYP19A1 
Since the patient showed symptoms of aromatase deficiency as indicated by genital virilization, we 
were particularly interested in examining the role of R550W mutation in POR on the CYP19A1 activity. 
Compared to other cytochromes P450 studied in this report, CYP19A1 requires additional steps of 
electron transfer from POR to complete a single reaction cycle, and therefore, is predicted to be severely 
affected by changes in POR that affect electron transfer from POR to CYP19A1. The POR-R550W 
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R550W was reduced to 16% of WT-POR and 25% of residual activity was observed in CYP19A1 
reaction kinetics, due to a slight decrease in Km for the androstenedione observed in reactions supported 
by POR-R550W (Table 3). A significant loss of CYP19A1 activity confirmed the diagnosis of 
aromatase deficiency and genital virilization in the patient. 
 
CYP2C9 Activity 
We tested the activity of CYP2C9 supported by the WT and R550W variant of POR in a reconstituted 
system. Compared to WT POR activity of CYP2C9 supported by R550W variant of POR was severely 
reduced to 2.5% of the WT-POR (Figure 8A). This almost complete loss of activity compared to WT 
POR indicated a severe effect on drug metabolism supported by CYP2C9. 
 
CYP2C19 Activity 
The activity of CYP2C19 was tested with both the WT and R550W variant of POR. We found that in 
CYP2C19 assays, the R550W variant of POR showed only 2.9% of the WT POR activity (Figure 8B). 
The effect of R550W variation in POR on CYP2C19 was also severe, indicating a highly reduced 
capacity of drug metabolism reactions by CYP2C19. 
 
CYP3A4 Activity 
The R550W variant of POR showed only 10.2 % activity in CYP3A4 assays as compared to the WT-
POR enzyme (Figure 8C). The loss of activities for drug-metabolizing cytochrome P450 enzyme-
CYP3A4 by the POR variant R550W indicates problems with POR-P450 interactions which seem to 
be different for different cytochrome P450 partners. 
 
CYP3A5 Activity 
The R550W variant of POR had only 31.4% of the WT activity in CYP3A5 assay (Figure 8D). This 
was different from the results obtained for the CYP3A4 activity assays, indicating there are differences 
in the interaction of POR with these two closely related cytochrome P450 proteins. The effect of R550W 
variation in POR on CYP3A5 was not as strong as in case of CYP3A4 activity, but the loss of activity 
was still more than 50%, indicating a reduced capacity of drug metabolism reactions mediated by 
CYP3A5. CYP3A5 is involved in the metabolism of tacrolimus, an immunosuppressant drug used 
during organ transplants which has a narrow therapeutic index. 
 
The R550W mutation in POR affects NADPH binding. 
The structural analysis of the R550W mutation indicated an effect on NADPH. We sought to examine 
the impact of R550W mutation in POR on the utilization of NADPH using three different assays 
(Figure 9, Table 4). For examining the role of NADPH concentration in reactions supported by POR, 
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constant, and NADPH concentration was varied. In the cytochrome c reduction assay, a fivefold 
increase in Km for NADPH was observed for the POR-R550W compared to the WT-POR (Figure 9A). 
A similar effect was also observed using MTT reduction assay with a 4.8-fold increase in Km for 
NADPH for the POR-R550W compared to WT POR (Figure 9B). We also performed the CYP19A1 
assay with varying concentrations of NADPH and observed a severe loss of CYP19A1 activity for the 
POR-R550W (Figure 9C, 10A). In the CYP19A1 assay, a direct evaluation of NADPH oxidation could 
not be made as the final product was the metabolism of androstenedione into estrone, but the loss of 
protein-protein interaction coupled with the loss of flavins in POR-R550W would severely limit the 
activity of CYP19A1 due to multiple interactions required for completion of one catalytic cycle. At a 
fixed (100 nM) substrate concentration of androstenedione, The CYP19A1 activity supported by POR-
R550W was only 8.5% of POR-WT (Figure 10B). 
 
Discussion  
In this report, we have investigated the cause of CYP19A1 deficiency manifested not by any changes 
in CYP19A1 itself but by a novel mutation in POR. A comprehensive examination of multiple 
cytochrome P450 enzymes encompassing both the steroid as well as drug-metabolizing activities was 
performed, which showed severe inhibition of multiple enzyme activities due to the R550W mutation 
in POR. Severe inhibition of CYP19A1 activity due to the R550W mutation in POR corroborates our 
previous hypothesis of both the virilization of the patient as well as maternal virilization during 
pregnancy due to the mutation in POR affecting CYP19A1 activity. The results described here also 
show that in severe cases of POR deficiency, the steroid as well as drug-metabolizing cytochrome P450 
enzyme activities, that are dependent on POR, may be affected.  
 
Remarkably, although the R550 residue is not directly involved in either the FAD or FMN binding in 
POR, a loss of one-third of flavin content, for both the FAD as well as FMN was observed. Previously 
we have shown that mutations in POR may cause protein instability which may ultimately lead to loss 
of flavin cofactors. A reduction in flavin content by itself does not explain the severe loss of activities 
of all cytochrome P450 enzymes studied.  Consistent with this, some of the small molecule substrates 
of POR, that can be reduced through FAD (FeCN) or requiring FMN (MTT) were only moderately 
affected, indicating protein-protein interactions play a vital role in the overall effect of R550W mutation 
in POR. The CYP19A1, requiring several electron transfer steps for its metabolic reactions, is affected 
to a greater extent compared to activities of POR towards small-molecule substrates. The overall effects 
of R550W mutation on steroid metabolism may be more complicated due to inhibition of several 
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The patient, an individual with 46, XX DSD, presented signs of prenatal aromatase deficiency as 
indicated from strong maternal virilization during pregnancy with highly elevated serum T levels at 
delivery that returned to normal, newborn ambiguous genitalia with elevated T for the female sex, and 
slightly elevated 17OH-P that progressively diminished. CYP19A1 gene analysis was normal, and it 
was not until seven years later that compound heterozygous POR gene variants were detected by using 
a panel of candidate genes for DSD in DNA samples from DSD patients lacking a molecular diagnosis. 
Clinical and biochemical control at prepubertal age (8 years) revealed normal skeletal growth, normal 
baseline adrenal function (cortisol and ACTH), although with an elevated 17OH-P. 
 
The allele c.73_74delCT/p.Leu25Phefs*93 is predicted to be a null allele resulting from a premature 
stop codon truncated at amino acid position 93 out of 680 residues in POR protein. Therefore, the 
protein encoded by the c.1648C>T/p.Arg550Trp allele would be responsible for the patient’s 
phenotype. Prenatal and neonatal phenotype predicted a severe aromatase deficiency, whereas the 
elevated 17-OH-P, although with normal cortisol and ACTH, may have indicated the presence of mild 
21-hydroxylase and 17,20-lyase deficiencies. The mutation Arg550Trp is located in the NADPH 
binding region of POR. Computational analysis predicted instability in the NADPH binding region of 
POR by R550W mutation due to the disruption of hydrogen bonding, which may affect cytochrome 
P450 activities to a higher degree than small-molecule partners. Computationally predicted negative 
effects of R550W mutation in POR on several cytochrome P450 activities as well as binding of 
NADPH, were confirmed by experiments using recombinant proteins. These results suggest a 
pathological effect of POR R550W and a diagnosis of PORD in the patient with 
p.Arg550Trp/p.Leu25PhefsTer93 in POR. The 46, XX patient and her mother presented prenatal 
aromatase deficiency; at prepubertal age and without steroid hormone replacement therapy growth is 
normal and baseline adrenal function is normal (cortisol and ACTH) although the increased level of 17-
OH-P demonstrates a mild 21-hydroxylase deficiency. In PORD, 46, XX neonate may be virilized at 
birth due to effects of prenatal androgens produced by alternate pathway (62,63) but postnatal 
virilization may not progress before pubertal age. After birth, alternate pathway is suppressed and a sex 
steroid deficiency would become visible with age. Further changes may occur during puberty including 
hypergonadotropic hypogonadism and enlarged ovarian cysts. Due to reduced  CYP19A1 activity, it is 
predicted that aromatase deficiency will manifest at pubertal age, most probably needing sex hormone 
replacement therapy and interfering with future fertility while adrenal function will need to be 
monitored.  
 
An increase in steroids produced through the alternate (backdoor) pathway of biosynthesis could also 
be an indicator of PORD (62-66). Production of DHT from alternate pathway involving POR and 
CYP17A1 as well as AKR1C2 and AKR1C4 has been described in humans (67,68). Lower levels of 
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deficiency (65). Another explanation for hyperandrogenism during pregnancy is the formation of DHT 
from the alternate pathway, that could not be efficiently metabolized by mother (62,64). Production of 
androgens via 17-hydroxyprogesterone (17-OH-P) through the alternate pathway has been 
demonstrated in neonates with P450 oxidoreductase deficiency during the first weeks of life (62). 
Currently, long term outcomes of patients with PORD are not available and follow-up of patients over 
the years may provide further details about the role of different steroid metabolites as well as the impact 
of prenatal exposure to DHT produced via alternate pathway in 46, XX patients. In addition, 
consideration should also be given to combined effects of variations in POR as well as cytochrome 
P450 enzymes as demonstrated for the common polymorphism of CYP19A1 and variant forms of POR 
(69). 
 
From the therapeutic perspective, supplementation with steroids is a viable and commonly used option 
to treat POR deficiency, especially when the loss of exact metabolites can be measured in the serum or 
urine of patients by use of GC-MS or other methods (9,70,71). A low dose of glucocorticoid 
supplementation is often prescribed. The need for glucocorticoid replacement could be determined via 
ACTH stimulation tests. In 46, XX patients showing signs of aromatase deficiency, estrogen 
replacement may be needed. However, the implications of a defect in drug metabolizing enzymes 
observed here for POR-R550W as well as other mutations in POR need to be considered. Several 
hepatic drug metabolizing cytochrome P450 enzymes that show reduced activities due to mutations in 
POR are involved in the metabolism of both estrogens as well as androgens (e.g. CYP3A4) (58,59,72). 
Transdermal estrogen patches are suggested as an option to bypass the effects of hepatic metabolism 
(65,73).   However, long term effect of multi steroid supplementation may have unknown side effects 
on normal growth and development, and therefore, an accurate characterization of individual variations 
in POR is required to characterize the effects of different steps in steroid metabolism and tailor the 
therapeutic interventions based on personalized steroid and enzyme activity profiles (74). A detailed 
characterization of the effects of POR mutation R550W on multiple enzymes described is a step towards 
this goal of personalized medicine.  
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Figure 1. Role of POR in supporting the activities of drug and steroid metabolizing cytochrome P450 
enzymes. POR is a flavoprotein containing co-factors FAD and FMN. Cytochrome P450 proteins found 
in endoplasmic reticulum metabolize a wide range of molecules, including steroid hormones and drugs. 
Energy requirements for the metabolic reactions of cytochrome P450 located in the endoplasmic 
reticulum are provided by NADPH. POR binds NADPH and undergoes conformation changes to 
transfer electrons from NADPH to FMN via FAD. Interaction of POR with P450 proteins results in 
further electron transfer from FMN bound to POR to the heme group of cytochrome P450. In this 
metabolic process, NADPH is reduced by POR to form NADP+. 
 
Figure 2. Role of POR in steroid and drug metabolism. POR is necessary for the metabolic activities 
of cytochrome P450 proteins located in the endoplasmic reticulum. These include the steroid 
metabolizing cytochromes P450 CYP17A1, CYP21A2, CYP19A1, CYP51A1 and CYP26B1 as well 
as drug metabolizing cytochromes P450 CYP3A4, CYP3A5, CYP2D6, CYP2C9 and CYP2C19. A 
reduction in POR activity may lead to loss of both the steroid as well as drug metabolizing activities. 
Further considerations might be required during steroid supplementation for the treatment of PORD as 
drug metabolizing enzymes like CYP3A4 can also cause hepatic metabolism of estrogens and 
androgens, and altered activities of some of these hepatic cytochrome P450 enzymes may complicate 
the dose requirements for steroid supplements.   
 
Figure 3: Family tree and genetic analysis of POR sequences. 
The DNA samples were analyzed with a custom-designed targeted Disorders of Sexual Development 
NGS panel (DSDSeq.V1, 111 genes, and three regulatory regions) using SeqCap EZ technology (Roche 
Nimblegen) and sequenced on a NextSeq (Illumina) platform. Sequence variations retained as 
candidates were verified by Sanger sequencing and DNA from parents were also analyzed as controls. 
(A) Compound heterozygous variants within the POR gene were identified in the proband (II-1): 
c.73_74delCT (p.Leu25Phefs*93) located in exon 2, inherited from the mother (I-2), and a second 
variant c.1648C>T (p.Arg550Trp) in exon 13, inherited from the father (I-1). Parents are both carriers 
for each variant, and her brother (II-2) is a carrier for c.1648C>T (p.Arg550Trp). The arrow indicates 
the proband. N indicates normal allele. (B) Chromatogram of the variants in the POR gene 
(NM_000941) in this family. The arrows indicate the variant location. 
 
Figure 4: Structural analysis of POR-R550W. (A). Location of R550W residue in POR. (B) R550 is 
not directly at the surface of POR. (C) Arginine 550 forms hydrogen bonds with threonine 529 to 
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Figure 5: Flavin content of POR-WT and POR-R550W. Flavin content of the POR proteins was 
analyzed by boiling the proteins under selective pH conditions. Relative fluorescence unit (RFU) of the 
flavins released from the POR variants measured at (A) pH 7.7 (FMN or F7.7) and (B) pH 2.6 (FAD or 
F2.6) are shown. The RFU of WT POR was fixed as a hundred percent. Data are shown as mean ± SEM 
of two experiments done in triplicates. 
 
Figure 6: Cytochrome c, MTT, and Ferricyanide reduction assay with POR-WT and POR-
R550W. (A) Cytochrome c (B) MTT (C) ferricyanide reduction assays were performed with the WT 
and POR-R550W variant. Kinetic assays were performed by monitoring the changes in absorbance at 
550 nm for cytochrome c, 610 nm for MTT, and 420 nm for ferricyanide reduction. Data were fitted to 
the Michaelis-Menten kinetics model and analyzed using GraphPad Prism. The calculated Km and 
Vmax values are presented in Table 1. Data are shown as mean ± SEM of three independent replicates. 
 
Figure 7: Enzymatic activities of steroid metabolizing cytochrome P450 supported by POR-WT 
or POR-R550W. A. Enzymatic activity of CYP17A1 supported by POR-WT and POR-R550W. 
Purified, recombinant CYP17A1 and enriched bacterial membranes containing POR proteins were 
reconstituted, and their activity to convert [14C] labeled Progesterone into 17OH-progesterone was 
tested by TLC and phosphorimager analysis. Data were analyzed using the Michaelis-Menten kinetics 
with GraphPad Prism. The calculated Km and Vmax values are shown in Table 3. B. Enzymatic activity 
of CYP21A2 supported by POR-WT and POR-R550W. The in-vitro reconstituted system was prepared 
by mixing purified CYP21A2, and bacterial membranes containing POR proteins and their activity to 
convert [14C] labeled Progesterone to 21OH-Progesterone was measured by TLC and phosphorimager 
analysis. Data were analyzed using the Michaelis-Menten kinetics with GraphPad Prism. The calculated 
Km and Vmax values are shown in Table 3. C. Enzymatic activity of CYP19A1 supported by POR-
WT and POR-R550W. Bacterially expressed, purified, recombinant CYP19A1, and the enriched 
bacterial membranes containing POR proteins were mixed, and their activity to convert [3H] labeled 
androstenedione to estrone was tested by the tritiated water release assay. Data were analyzed using the 
Michaelis-Menten kinetics with GraphPad Prism. The calculated Km and Vmax values are shown in 
Table 3. Data are shown as mean ± SEM of two independent replicates.  
 
 
Figure 8: Activities of drug-metabolizing cytochromes P450 supported by POR-WT or POR-
R550W. A. Activity of cytochrome P450 CYP2C9 supported by POR-WT and POR-R550W. Assay of 
CYP2C9 activity was performed to compare POR-WT and POR-R550W by using 20 µM BOMCC as 
a substrate. Activity with the WT POR was fixed as a hundred percent, and results are given as a 
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triplicates. B. The activity of cytochrome P450 CYP2C19 supported by POR-WT and POR-R550W. 
Assay of CYP2C19 activity was performed to compare POR-WT and POR-R550W by using 20 µM 
EOMCC as a substrate. Activity with the WT POR was fixed as a hundred percent, and results are given 
as a percentage of WT activity. Data are shown as mean ± SEM from two experiments performed in 
triplicates. C. The activity of cytochrome P450 CYP3A4 supported by POR-WT and POR-R550W. 
Assay of CYP3A4 activity was performed to compare POR-WT and POR-R550W by using 20 µM 
BOMCC as a substrate. Activity with the WT POR was fixed as a hundred percent, and results are given 
as a percentage of WT activity. Data are shown as mean ± SEM from two experiments performed in 
triplicates. D. The activity of cytochrome P450 CYP3A5 supported by POR-WT and POR-R550W. 
Assay of CYP3A5 activity was performed to compare POR-WT and POR-R550W by using BOMCC 
as a substrate. Activity with the WT POR was fixed as a hundred percent, and results are given as a 
percentage of WT activity. Data are shown as mean ± SEM from two experiments performed in 
triplicates. 
 
Figure 9: Co-factor dependence of R550W mutation in POR. Since the R550 residue is located near 
the NADPH binding site in POR, we sought to examine the role of NADPH variation and binding to 
R550W-POR. A. Assay of cytochrome c reduction activity with increasing NADPH concentration. In 
R550W-POR affinity for NADPH was diminished as indicated by a fivefold increase in KM for 
NADPH. B. Assay of MTT reduction activity with increasing NADPH concentration. Affinity for 
R550W-POR was also found to be lower as deduced from more than fourfold increase in Km for 
NADPH compared to WT-POR. C. CYP19A1 assay with increasing concentrations of NADPH. The 
POR-R550W showed a severe loss of activity in the CYP19A1 assay. In the CYP19A1 assays with 
varying NADPH concentration, the activity using the POR-R550W was too low to allow a reliable 
estimation of kinetic parameters, and reaction being monitored was a couple assay (aromatase activity 
using androstedione), therefore, calculation of kinetic parameters for NADPH reduction were not made. 
Data are shown as mean ± SEM of three independent replicates. 
 
Figure 10: Decrease in CYP19A1 activity due to POR-R550W mutation in POR. A. A bar chart 
showing CYP19A1 activity supported by POR-WT and POR-R550W at different concentrations of 
NADPH. The POR-R550W showed a severe loss of activity in the CYP19A1 assays. B. CYP19A1 
activity using 100 nM androstedione as substrate. The activity supported by R550-W variant of POR 
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Table 1. Hormone analyses of the patient and her mother. ACTH: adrenocorticotropic hormone 
(pg/ml); DHEA-S: dehydroepiandrosterone sulphate (µg/dL); 17-OH-P: 17-hydroxy-progesterone 
(ng/dL); cortisol (µg/dL); T: testosterone (ng/dL); E2: estradiol (ng/dL).  
 
 
 ACTH DHEA-S 17-OH-P Cortisol T E2 
 pg/ml µg/dL ng/dL µg/dL ng/dL ng/dL 
Mother (5th day post-partum)  167.4 150  545 11.1 
Mother (4th month post-
partum) 
    26  
Normal values (women: 
follicular phase) 
 98.8-340.0 19-182  6-82 1.2-16.6 
       
Patient (7 days)   4,700  84  
Patient (19 days)   2,100  36  
Patient (1 month 4 days)   2,400  29  
Patient (1 month 18 days)   1,510  17  
Patient (7 months)   590  2  
Patient (8 years) 65.2 47.1 10,400 14.3 < 7  
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Table 2: Population distribution of POR variations reported in this study.  
 




Ref Allele Alt Allele 
R550W rs782551896      
  TopMed Global 125568 C=0.99996 T=0.00004 
  gnomAD-
Exomes 
Global 171252 C=0.99995 T=0.00005 
  gnomAD-
Exomes 
European 87224 C=0.9999 T=0.0001 
  gnomAD-
Exomes 
Asian 35462 C=1.000 T=0.000 
  gnomAD-
Exomes 
American 26414 C=0.9999 T=0.0001 
  gnomAD-
Exomes 





7850 C=1.000 T=0.000 
  gnomAD-
Exomes 
Other 4604 C=1.00 T=0.00 
       
R550Q rs1320059073      
  TopMed Global 125568 G=0.99993 A=0.00007 




     
  TopMed Global 125568  delCT=0.00001 
  gnomAD-
Exomes 
Global 246148  delCT=0.00001 
  gnomAD-
Exomes 
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Table 3: Kinetic parameters for activities of cytochrome c, MTT, ferricyanide reduction, and 
CYP17A1, CYP21A2 and CYP19A1 activities supported by POR-WT and POR-R550W. For the 
cytochrome c, MTT and Ferricyanide reduction assay, the NADPH concentration was fixed at 100 M 
and varying concentrations of the substrate were used for the analysis. For the conversion of 
androstenedione to estrone (CYP19A1 activity), NADPH was fixed at 1 mM, and variable 
concentrations (10–1000 nM) of androstenedione were used. For the conversion of Progesterone to 
17OH Progesterone (CYP17A1 activity) or Progesterone to 21OH Progesterone (CYP21A2 activity), 
NADPH was fixed at 2 mM, and variable concentrations (0.3–5 µM) of Progesterone were used. Data 
are shown as mean ± SEM of independent replicates (n=3 for small molecule reduction assays and n=2 








Vmax/Km % WT 
Cytochrome c reduction assay      
POR-WT 873±68 23.7±3.7 36.8 100 
POR-R550W 267±30 17.8±4.3 15 40.8 
MTT reduction assay      
POR-WT 1254±23 21.3±1.5 58.9 100 
POR-R550W 916±24 201±11.7 4.6 7.7 
Ferricyanide reduction assay      
POR-WT 3890±88 27.2±2.3 143 100 
POR-R550W 2939±712 74.8±54 39.3 27.5 





Km (µM)  Vmax/Km % WT 
CYP19A1; aromatase (androstenedione to estrone) 
POR-WT 0.042±0.003 0.24±0.05 0.173 100 
POR-R550W 0.007±0.002 0.15±0.17 0.044 25.1 
     
CYP17A1; (Progesterone to 17OH-Progesterone ) 
POR-WT 8.2±0.47 1.3±0.22 6.2 100 
POR-R550W 0.3±0.004 1.3±0.5 0.2 3.4 
     
CYP21A2; (Progesterone to 21OH-Progesterone) 
POR-WT 32.5±7.9 2.2±1.28 14.8 100 










niversitaetsbibliothek Bern,  am
it@













Table 4: Effect of NADPH variation on activities supported by POR-WT and POR-R550W. To 
measure the effect of NADPH variation on activities of POR-WT and POR-R550W activities were 
measured using fixed concentrations of cytochrome c (40 µM), MTT (500 µM) and androstenedione 
(100 nM) while the NADPH concentrations in the assays were varied from 0 to 1000 µM. Data are 
shown as mean ± SEM of independent replicates (n=3). In the assay of CYP19A1 activity with 
variable NADPH, the activity of CYP19A1 supported by POR-R550W was too low for kinetic 
parameters to be calculated with reliability. For CYP19A1 assay, “nd” indicates activity too low 









Cytochrome c reduction   
POR-WT 611.8±14 8±0.7 76.1 100 
POR-R550W 434±33.6 30.4±5.7 14.3 18.8 
 
MTT reduction   
POR-WT 994.1±58 12.3±2.3 81 100 
POR-R550W 950.1±52 58.4±6.3 16 20 
 
CYP19A1 (Androstenedione to Estrone) 
pmol/min/nmol 
P450  
   
POR-WT 0.13±0.003 11.3±3.4 0.011 100 
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